and IL-10 normalized, while this was not the case for IFN-g, IL-2, IL-17, and IP-10 levels. In HIV þ TST þ patients on HAART, levels of IFN-g, IL-17, IL-10 and MIP-1a normalized, while no change in the levels of IL-2 and IP-10 were observed.
In conclusion, the simultaneous measurement of IFN-g, IL-17 and IP-10 may assist in diagnosing LTBI; IL-2 and IP-10 may assist in diagnosing active TB; while IFN-g, IL-17, MIP-1a, and IL-10 levels could help to discriminate LTBI and active TB. In addition, IL-10 and MIP-1a levels could help to monitor responses to TB treatment and HAART.
Introduction
Despite that nearly 20 million lifes have been saved from tuberculosis (TB) associated deaths in the past 17 years, and mortality from TB has decreased by 41% since 1990, TB remains a major health problem particularly in developing countries where 90% of TB incidence and death occurs. In 2011, there were 8.8 million incident TB cases (13% co-infected with HIV) and 1.4 million deaths from TB worldwide [1] .
Due to the lack of an effective vaccine, control of TB largely depends on the diagnosis and treatment of active TB [2] . However, Acid Fast Bacilli (AFB) smear sputum microscopy, the gold standard for active TB diagnosis especially in resource limited settings where TB is endemic, has low sensitivity (50e70%) [3] especially in individuals coinfected with HIV (~35%) [4] and children (<50%) [5] . In addition, Mtb sputum culture has limitations including the relatively higher costs per test, long time to get results (4e8 weeks) and requirement of higher expertise and laboratory infrastructure [3] . Moreover, the current recommended regimen for treatment of active TB is requiring a minimum of 6 months to complete and is often hampered by non-adherence and drug-related toxicity.
Nonetheless, treatment of asymptomatic latent TB infection (LTBI), which is recommended when the risk of reactivation is high, is a critical strategy to control TB [6] . The role of the century old Tuberculin Skin Test (TST) and the recently emerged IFN-g release assay (IGRA) is important to diagnose LTBI [7] . However, TST and IGRA have low sensitivity and specificity especially in malnutritioned and HIV infected individuals [8] . The fact that TST and IGRAs are dependent on the detection of a single biomarker, IFN-g [9] , is the main reason for the lower performance of both TST as well as IGRA [10] .
Based on the notion that Mtb infection is associated with a spectrum of overlapping clinical conditions which can be poorly separated, there is a need to identify additional biomarkers that correlate with the clinical stages of Mtb infection. This could accelerate the development of novel diagnostic and therapeutic tools for both latent and active TB. Furthermore, for better utilization of TB biomarkers in clinical practice, the effect of HIV infection and therapy on the biomarker profile also needs to be investigated [11e13] .
The clinical outcome of Mtb infection is determined by a complex interplay of various cytokines intercellular signaling molecules that regulate the differentiation, proliferation, and activation of immune cells [14] ; and chemokines (8e10 kDa cytokines that direct cell migration) [15] . The main cytokines shown to be important in the occurrence, progression and control of TB infection are the pro-inflammatory (INF-g, TNF-a, IL-12, IL-2), inflammatory (IL-6, IL-17), and immunoregulatory cytokines (IL-10, TGFb) [16] . A combination of IP-10, IL-2 and TNF-a [17] , and IP-10 and IFN-g [18] , could be promising biomarkers for active TB diagnosis. IP-10 and MCP-2 were reported to be able to discriminate TB disease from latent infection [19] .
Besides that measuring of multiple pro-and anti-inflammatory cytokine/chemokines specific to TB will give insight into the pathogenesis mechanism of Mtb infection, it may also provide the opportunity to identify candidate immunologic biomarkers for TB disease and infection. Therefore, we measured the secretion of six cytokines [T helper cell (Th) type 1 (Th1) (INF-g, IL-12), IL-17 and IL-10], and two chemokines (IP-10, MIP-1a) after 7 day culture of whole blood stimulated with Early Secreted Antigenic Target-6/ Culture Filtrate Protein-10 (ESAT-6/CFP-10) antigen. Five clinical groups namely HIV
HIV À TST À were included in this study.
Materials and methods

Study population and samples
This observational cohort study was performed at St Peter Specialized Referral TB Hospital, Akaki and Kality Health centers, in Addis Ababa, Ethiopia from April 2007eFebruary 2011. Adults (age 18e69 years) of both sexes who were naïve to antiretroviral therapy (ART) and TB treatment were enrolled after informed and written consent was sought.
Diagnosis of active TB was based on both clinical and bacteriological evidence. At least two sputum smears were required to be microscopy positive for Acid Fast Bacilli (AFB) by Ziehl-Neelsen method [20] . Except for TB patients, TST test was performed for all participants by intradermally injecting 2 TU (tuberculinunit) of PPD RT23 (Staten Serum Institut, Copenhagen, Denmark) by Mantoux method. A diameter of skin induration was measured by a trained nurse after 48e72 h. The cut-off for TST positivity was !10 mm in HIV un-infected, and !5 mm in HIV-infected individuals [20] .
A total of 79 participants in five clinical groups were included in this study: 1) HIV positive TB patients (HIV þ TB þ , n ¼ 26) of whom 14 were on anti-TB treatment (ATT) and were followed-over a six month (M6) period, and 12 were on ATT plus HAART and were followed for 6 and 18 months; 2) HIV negative TB patients (HIV
, all were on ATT and followed for 6 month; , n ¼ 10). HAART and ATT were provided to the patients free of charge and according to the national guidelines [20] .
At enrollment and during the follow-up visit each participant was interviewed using a standard questionnaire and detailed clinical, anthropometric and demographic data were recorded by a clinician. A total of 20 ml heparinized venous blood was collected and transported to the Ethiopian Health and Nutrition Research Institute (EHNRI) for laboratory tests. All laboratory tests were performed by automated machines by adhering to the manufacturer's manual. Quantification of absolute counts of CD4þ T cells was performed using a FACScan (Becton Dickinson, San Jose, USA). Plasma HIV RNA load was determined using the NucliSens EasyQ NASBA diagnostic 2007/1 assay (Organon, Teknika) which quantifies HIV-1 with a linear dynamic range from 50 to 3,000,000 copies/ml.
Whole blood stimulation in vitro
We adopted a previously established whole blood assay (WBA) and determined cytokines in the supernatants [21] . Whole blood obtained from each participant before and after treatment was diluted 1 in 5 with complete Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma, cat R0883) supplemented with 10% Fetal Calf Serum (FCS) (Invitrogen, cat 10106169), and 1% Penicillin/ Streptomycin (P/S). Then 100ul of blood/well was transferred in triplicate in round-bottom microtiter plates (Nunclon Surface; NUNC; Roskilde, Denmark) which has been coated with ESAT-6/ CFP-10, and Culture Medium (RPMI 1640) as negative Control.
The final concentration of ESAT-6/CFP-10 was 10 mg/ml. Culture plates were incubated in a 5% CO 2 incubator at 37 C for 7 days, and supernatants were collected and stored at À80 for further analysis. The ESAT-6/CFP-10 fusion protein was produced at the department of Infectious Diseases, Leiden University Medical Center [22] .
Measurement of cytokine/chemokine biomarkers
The level of 4 cytokines (IFN-g, IL-2, IL-17, IL-10) and two chemokines (IP-10,MIP-1a) was measured in the 7th day whole blood culture supernatant using xMAP technology (Luminex, Austin TX, USA) using a biorad FlexMap3D system (biorad USA). Acquisition was performed using xPonent 4.2 software (Luminex) and data analysis was performed using BioPlex Manager 6.1.1 (biorad) at the multiplex core facility of the University Medical Center, Utrecht (UMCU), The Netherlands, as described previously [23] .
Data analysis
Initially, the value of each cytokine/chemokine measured after no stimulation (RPMI medium) was subtracted from that of ESAT-6/ CFP-10 induced cytokine/chemokines. After background subtraction, negative values were converted to zero. The value of the cytokine induced after no stimuli (RPMI medium) by each clinical group at baseline are shown in the Supplementary Table 3 .
One-way analysis of variance to test if all the means of a specific cytokine/chemokine induced by each clinical groups were equal (null hypothesis), showed the F statistic was significant for all the cytokine/chemokines, indicating that at least some of the means must differ from one other. Hence, we examined the pair-wise difference between the groups without adjusting for multiple comparisons. Thus, nonparametric statistical methods (Wilcoxon signed rank test for paired data, ManneWhitney u tests for unpaired data, and KruskaleWallis tests for data from different groups) were performed to compare differences within and between groups. Spearman's rank correlation analysis was performed between cytokines/chemokines within each patient group. All data analysis was done using Intercooled STATA version 11.0 (College Station, Texas, USA). A p-value of <0.05 was considered significant.
Results
Study population characteristics at baseline
The demographic, clinical and laboratory characteristics of the study populations are shown in Table 1 
Comparison of cytokine/chemokine responses to Mtb antigen at baseline
Comparison of the concentration of each cytokine in response to ESAT-6/CFP-10 stimulation among the five clinical groups at baseline is shown in Figure 1 and 2 ).
The effect of HIV coinfection on Mtb specific immune response
We next studied the effect of HIV coinfection on the cytokine/ chemokine response to ESAT-6/CFP-10 ( Figures 1 and 3) . Interestingly, HIV infection lead to lower secretion of Th1-derived cytokines (IFN-g, IL-2), IL-17 and IP-10 in active TB patients (HIV Analysis of the cellular immune responses after therapy provides novel opportunities to understand the complex pathogenesis mechanism of Mtb infection as well as identify biomarkers for monitoring treatment effect. Therefore, we measured the dynamics Table 1 Baseline demographic and clinical characteristics of the 5 clinical groups (n ¼ 79). of the cytokine response to ESAT-6/CFP-10 in patients who were on ATT and/or HAART (Figures 3 and 4) . In the HIV Of special interest, this study showed a distinctive expression pattern of the chemoattractants (MIP-1a and IP-10) and IL-10 in response to therapy (Figures 3 and 4) . Whereas the concentration of both IL-10 and MIP-1a normalized in all the patients by M6 of ATT, ATT plus HAART, and HAART, respectively; there was no significant change in the level of IP-10 in HIV In the HIV þ TSTþ patients on HAART ( Figure 5B ), we found a decrease in IL-17/IL-10 and IL-2/IL-10 by M6 and M18 (a shift to Th2), but a sharp increase in IFN-g/IL-10 by M18 (a shift to Th1).
The results suggested that IL-7/IL-10 and IL-2/IL-10 ratios could be used to monitor TB treatment and HAART responses, except in HIV þ TBþ patients. IFN-g/IL-10 ratio behaves differently relative to the IL-17/IL-10 and IL-2/IL-10 ratio in all the clinical groups, which indicates less value of IFN-g/IL-10 to monitor therapy responses
Discussion
In this study, the levels of four cytokines (INF-g, IL-12, IL-10, IL-17) and two chemokines (MIP-1a, IP-10) in a 7 day culture supernatants of whole blood stimulated with ESAT-6/CFP-10 antigen were compared in five clinical groups
þ and controls (HIV À TST þ ) before and after treatment. As a result, candidate cytokine/chemokine biomarkers that may serve as diagnostic and prognostic markers for TB were identified. We use a 7 day culture system as compared to the more conventional in vitro overnight stimulation assays like the antigeninduced proliferation and Interferon secretion, due to the reasons that, the whole blood assays, as compared to the standard assays using PBMC, are relatively simple, require less manipulation and can be used with small quantities of blood, and thus could be used in endemic field situation.
Distinct expression of cytokines in LTBI individuals
The increased expression of IFN-g, IP-10 and IL-17 cytokines in LTBI individuals (HIV À TST þ ) relative to healthy controls (Figures 1  and 2 ), indicates that immune cells producing these cytokines are abundantly present in most LTBI individuals [7] . Our results suggest that simultaneous measurement of these cytokine/chemokines could increase the accuracy to predict and diagnose LTBI. To support this, previous studies indicated the value of IP-10, IFN-g and IL-2 [24] , and IP-10 and MCP-2 [19] , to diagnose LTBI. Even more, since IP-10 is produced by a variety of cells (neutrophils, monocytes, endothelial cells and fibroblasts) which are less affected by HIV infection [25] , detection of IP-10 could improve the sensitivity to diagnose LTBI in populations with HIV infection [26, 27] .
Distinct expression of cytokines in active TB patients
In agreement with other reports [27] active TB patients (HIV À TB þ ) in this study showed elevated expression of IL-2 and IP-10 ( Figures 1 and 2) , which suggest that combined assessment of these cytokines may assist in the prediction and diagnosis of active TB. Indeed, others showed that combined detection of IP-10, IFN-g and MIP-1b 27]; IFN-g, IP-10 with MIG [27] ; IP-10, IL-2 with TNF-a [17] , and IP-10 with IFN-g [18] , in response to Mtb specific antigens, improved diagnostic performance for active pulmonary TB. However, the secretion of IFN-g, IL-2 and IP-10 at baseline was suppressed in active TB patients coinfected with HIV (Figures 1 and 3) , which could be due to a reduction in the number and functionality of Mtb and HIV specific T cells and macrophages due to infection with Mtb, HIV or TB/HIV [28] . Thus, the value of IFN-g, IL-2 and IP-10 to diagnose active TB could be compromised during HIV coinfection. 
Distinct expression of cytokines between LTBI individuals and active TB patients
Identification of stage specific cellular biomarkers which can accurately discriminate LTBI from active TB could play a significant role in control of TB [8] . In this study, HIV À TST þ individuals showed elevated IFN-g, IL-17, IL-10 and MIP-1a response to ESAT-6/CFP-10 antigen stimulation compared to HIV À TB þ patients, which suggests that simultaneous analysis of these cytokines can discriminate LTBI from active TB, which is in agreement to other studies [29, 30] . However, IP-10 appears to be less relevant to distinguish LTBI from active TB in this study as reported by others [31] .
The distinctive expression of cytokine/chemokines in LTBI and active TB groups in the present study also indicates the role of these cytokine in the pathogenesis of Mtb infection. Whereas increased secretion of Th1 (IFN-g) Similarly a recent study done in Ethiopia showed that anti TB treatment significantly improves the plasma level of Th1 cytokines and level of chemokines in HIV negative TB patients [33] .Thus, our results suggests a role for IL-10, IFN-g, IL-2, MIP-1a, and IP-10 in the pathogenesis of TB on hand, and their value to monitor TB treatment. Others also showed the value of plasma IP-10 [34] and IFN-g De [35] , and IP-10 and IFN-g in response to ESAT-6 and CFP-10 stimulation [36] to monitor TB treatment in HIV negative TB patients. (Figure 4) . Similarly a recent study done in Ethiopia, showed no restoration of the plasma level of Th1 cytokines in HIV positive individuals after anti TB treatment [33] . Our results support the scenario of early HAART initiation in TB/HIV patients [1] which could boost optimal Mtb specific immune restoration. Nonetheless, we found persistently lower and weaker Th1 derived cytokines in the HIV þ TBþ patients on ATT and HAART, which is similar to other reports [37] . This could be due to inefficient therapy, lack of treatment compliance [34] , and exhaustion of the immune system to produce these Th1 derived cytokines [9] . However, there was a sharp increase in Th1/IL-10 ratio in the HIV þ TB þ patients by six month of ATT and HAART ( Figure 5 ), which is similar to previous reports [37] . This might reflect the occurrence of IRIS which can developed within a month to even years after commencing HAART [38] . Our results suggest, therefore, the need for diagnosis and management of IRIS in TB/HIV patients initiated HAART in settings like in Ethiopia where TB and HIV are endemic and access to ART is expanding [39] .
The effect of HAART on cytokine/chemokine responses in HIV þ TSTþ patients
Chronic immune activation, inflammation, and immune dysfunction which cause non-AIDS pathologies including lymphoid fibrosis, cardiovascular diseases, lipoatrophy, and osteoporosis persist despite potent ART. Understanding the dynamics of antigen- specific immune responses in HIV patients on HAART, may assist to identify biomarkers for ART monitoring, as well as to develop effective therapeutic strategies for the non-AIDS comorbdites and for HIV cure [40, 41] . The progressive reduction in the proinflammatory cytokines (IL-2, IL-17, IL-2/IL-10 and IL-17/IL-10), but progressive increase in the anti-inflammatory cytokine (IL-10), and the chemoattractant (MIP-1a) in HIV þ TSTþ patients ( Figure 5 ), indicates the value of these cytokines to predict HIV disease progression, and also to monitor HAART outcomes in HIV patients. It seems that the Th1 and Th2 response in HIV patients on HAART behave in opposite direction. Others also showed a progressive increase in IL-10 [42] ; IL-12 and IFN-g [43] ; but a decrease in IP-10 [44] in HIV patients on HAART. Our data indicate that HAART benefits HIV patients not only by inhibiting virus replication but also by adjusting pro-and anti-inflammatory cytokine production. The dynamics of cytokine/chemokines in response to therapy might have long-term implication for progression or regression of the immunological health of HIV patients [43] , which strongly suggests the need to improve our understanding of when, where and how modulation of immune activation will be beneficial for HIV patients on HAART.
Of special interest, the level of IL-10 and MIP-1a normalized in HIV þ TBþ, HIV-TBþ and HIV þ TSTþ groups on standard therapy (Figure 4 ), which could indicate the value of both IL-10 and MIP-1a to predict HIV and TB disease progression and to monitor ATT and/ or HAART outcomes.
In summary, we showed distinct cytokine/chemokine production in response to ESAT-6/CFP-10 in LTBI and active TB groups. patients, can be useful surrogate biomarkers to monitor therapeutic responses and disease progression. However, further studies should be performed to validate the diagnostic and prognostic value of these cytokine/chemokine biomarkers by including latent Mtb antigens as stimulants; and larger groups of LTBI individuals, extra pulmonary TB patents and children where the need of better diagnostic methods is enormous.
